



b114353A

United States Patent [19][11] **Patent Number:** 6,114,353**Margolin**[45] **Date of Patent:** Sep. 5, 2000[54] **COMPOSITIONS AND METHOD FOR
TREATMENT OF LYMPHOMAS,
LEUKEMIAS, AND LEIOMYOMAS**[76] **Inventor:** Solomon B. Margolin, 6723 Desco Dr.,
Dallas, Tex. 75225[21] **Appl. No.:** 09/239,211[22] **Filed:** Jan. 28, 1999**Related U.S. Application Data**[63] Continuation-in-part of application No. 09/162,011, Sep. 28,
1998, which is a continuation-in-part of application No.
08/913,202, Sep. 3, 1997, abandoned, which is a continua-
tion-in-part of application No. PCT/US96/02737, Mar. 4,
1996, which is a continuation-in-part of application No.
08/397,962, Mar. 3, 1995, abandoned.[51] **Int. Cl.⁷** A61K 31/44; A61K 31/47[52] **U.S. Cl.** 514/313; 514/334; 514/336;
514/341; 514/342; 514/345[58] **Field of Search** 514/345, 342,
514/341, 336, 313, 334[56] **References Cited****U.S. PATENT DOCUMENTS**4,042,699 8/1977 Gadekar 514/345
4,052,509 10/1977 Gadekar 514/345*Primary Examiner*—Jerome D. Goldberg
Attorney, Agent, or Firm—John H. Crozier[57] **ABSTRACT**

In a preferred embodiment, drugs having chemotherapeutic properties which are useful against certain neoplastic disorders with wide safety margins as evidenced by their low toxicity, and molecular actions. Such drugs include as active ingredient(s) one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridone(s). The compositions of this invention are novel as anti-neoplastic drugs, namely as an agent for treating leukemias, lymphomas, and leiomyomas.

4 Claims, 4 Drawing Sheets

OFFICE OF THE COMPTROLLER OF THE PATENT OFFICE

Jusd'

21